Trial Profile
Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Liver disorders
- Focus Therapeutic Use
- Acronyms ARROW
- 28 Oct 2021 Status changed from active, no longer recruiting to discontinued due to organizational reasons
- 06 Oct 2020 Status changed from recruiting to active, no longer recruiting.
- 17 Sep 2019 Planned End Date changed from 1 Apr 2018 to 1 Mar 2021.